These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 26394118)

  • 21. Angiotensin II receptor blocker irbesartan attenuates cardiac dysfunction induced by myocardial infarction in the presence of renal failure.
    Watanabe R; Suzuki J; Wakayama K; Kumagai H; Ikeda Y; Akazawa H; Komuro I; Isobe M
    Hypertens Res; 2016 Apr; 39(4):237-44. PubMed ID: 26657004
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effects of irbesartan on nitric oxide system in the heart of diabetic rats].
    Qian XX; Chen YM; Wu WK; Liu Y; Zhou B; Liu JL; Chen L
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Sep; 26(9):1359-62. PubMed ID: 16982456
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis.
    Candido R; Allen TJ; Lassila M; Cao Z; Thallas V; Cooper ME; Jandeleit-Dahm KA
    Circulation; 2004 Mar; 109(12):1536-42. PubMed ID: 15023892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Triptolide combined with irbesartan synergistically blocks podocyte injury in a type 2 diabetes rat model].
    Ma RX; Xu Y; Zhang J; Li YS; Liu LQ
    Zhonghua Nei Ke Za Zhi; 2012 Feb; 51(2):117-22. PubMed ID: 22490812
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renal protection by low dose irbesartan in diabetic nephropathy is paralleled by a reduction of inflammation, not of endoplasmic reticulum stress.
    Hartner A; Cordasic N; Klanke B; Menendez-Castro C; Veelken R; Schmieder RE; Hilgers KF
    Biochim Biophys Acta; 2014 Apr; 1842(4):558-65. PubMed ID: 24418215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of integrin-linked kinase by angiotensin II receptor antagonist, irbesartan attenuates podocyte injury in diabetic rats.
    Dai HY; Zheng M; Tang RN; Ma KL; Ni J; Liu BC
    Chin Med J (Engl); 2012 Mar; 125(5):888-93. PubMed ID: 22490592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes.
    Burnier M; Zanchi A
    J Hypertens; 2006 Jan; 24(1):11-25. PubMed ID: 16331093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ; Lewis JB
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of fosinopril on chemerin and VEGF expression in diabetic nephropathy rats.
    Huang H; Hu L; Lin J; Zhu X; Cui W; Xu W
    Int J Clin Exp Pathol; 2015; 8(9):11470-4. PubMed ID: 26617877
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on streptozotocin-induced diabetic nephropathy.
    Sen S; Kanter M; Ustundag S; Aktas C; Dogutan H; Yalcin O
    Ren Fail; 2008; 30(10):1023-33. PubMed ID: 19016156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effect of Tripterygium glycosides on expression of hypoxia inducible factor-1α and endothelin-1 in kidney of diabetic rats].
    Chen WD; Chang BC; Zhang Y; Yang P; Liu L
    Nan Fang Yi Ke Da Xue Xue Bao; 2015 Apr; 35(4):499-505. PubMed ID: 25907932
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The protective effect of the RAS inhibitor on diabetic patients with nephropathy in the context of VEGF suppression.
    Chen HB; Lu JX; Li Q; Bao YQ; Tang JL; Lu HJ; Xiang KS; Jia WP
    Acta Pharmacol Sin; 2009 Feb; 30(2):242-50. PubMed ID: 19169272
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Irbesartan on Oxidative Stress and Serum Inflammatory Factors in Renal Tissues of Type 2 Diabetic Rats.
    Zhao X; Yang D; Xu W; Xu W; Guo Z
    J Coll Physicians Surg Pak; 2019 May; 29(5):422-425. PubMed ID: 31036110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy.
    Abdel-Wahab AF; Bamagous GA; Al-Harizy RM; ElSawy NA; Shahzad N; Ibrahim IA; Ghamdi SSA
    Biomed Pharmacother; 2018 Jul; 103():59-66. PubMed ID: 29635129
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Crosstalk relationship between adiponectin receptors, PPAR-γ and α-adrenoceptors in renal vasculature of diabetic WKYs.
    Afzal S; Sattar MA; Eseyin OA; Attiq A; Johns EJ
    Eur J Pharmacol; 2022 Feb; 917():174703. PubMed ID: 34973951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression.
    Matsui T; Yamagishi S; Takeuchi M; Ueda S; Fukami K; Okuda S
    Pharmacol Res; 2010 Jan; 61(1):34-9. PubMed ID: 19635564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial.
    Fernandez Juarez G; Luño J; Barrio V; de Vinuesa SG; Praga M; Goicoechea M; Cachofeiro V; Nieto J; Fernández Vega F; Tato A; Gutierrez E;
    Am J Kidney Dis; 2013 Feb; 61(2):211-8. PubMed ID: 22939518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension.
    Bonnet F; Cooper ME; Kawachi H; Allen TJ; Boner G; Cao Z
    Diabetologia; 2001 Jul; 44(7):874-7. PubMed ID: 11508272
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved gastric emptying in diabetic rats by irbesartan via decreased serum leptin and ameliorated gastric microcirculation.
    He L; Sun Y; Zhu Y; Ren R; Zhang Y; Wang F
    Genet Mol Res; 2014 Sep; 13(3):7163-72. PubMed ID: 25222222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.
    Berl T; Hunsicker LG; Lewis JB; Pfeffer MA; Porush JG; Rouleau JL; Drury PL; Esmatjes E; Hricik D; Parikh CR; Raz I; Vanhille P; Wiegmann TB; Wolfe BM; Locatelli F; Goldhaber SZ; Lewis EJ;
    Ann Intern Med; 2003 Apr; 138(7):542-9. PubMed ID: 12667024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.